SCHEMBL4298281

SCHEMBL4298281

CCOC(=O)c1cn(-c2cccc(OCC)c2)nc1C(F)(F)F

nearest known ligand 0.66

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
DGAT1 O75907 12/20 0.66
NPC1 O15118 2/20 0.48
ALDH1A1 P00352 1/20 0.48
POLB P06746 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
MAPK1 P28482 1/20 0.47
NPSR1 Q6W5P4 1/20 0.47
KLKB1 P03952 1/20 0.46
NOTUM Q6P988 2/20 0.46
RAB9A P51151 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL443532 0.89 DGAT1 (0.52) DGAT1NPC1ALDH1A1POLBSMN1; SMN2
SCHEMBL16691194 0.89 DGAT1 (0.55) DGAT1NPC1ALDH1A1POLBSMN1; SMN2
SCHEMBL4298343 0.88 DGAT1 (0.67) DGAT1NPC1ALDH1A1RAB9A
SCHEMBL4296607 0.88 DGAT1 (0.68) DGAT1KLKB1NOTUM
SCHEMBL4486967 0.88 DGAT1 (0.52) DGAT1NPC1ALDH1A1POLBSMN1; SMN2
SCHEMBL408172 0.87 NPSR1 (0.60) DGAT1NPC1ALDH1A1POLBSMN1; SMN2
SCHEMBL4299394 0.82 DGAT1 (0.61) DGAT1NPC1ALDH1A1MAPK1NPSR1
SCHEMBL408173 0.81 NPC1 (0.45) DGAT1NPC1MAPK1NPSR1RAB9A
SCHEMBL4300650 0.81 NPSR1 (0.59) DGAT1NPC1ALDH1A1SMN1; SMN2MAPK1
SCHEMBL19795577 0.81 JUN (0.50) DGAT1NPC1ALDH1A1MAPK1NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090286791-A1 Amide Compounds TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-11-19 US disclosed
US-20090286791-A1 Amide Compounds TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-11-19 US disclosed
US-20090286791-A1 Amide Compounds TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-11-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090286791-A1 Amide Compounds DLAT, DGAT2, DGAT1 DGAT1 3/4885NPC1 214/4885ALDH1A1 231/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.